Generic Acular LS Availability

See also: Generic Acular

Acular LS is a brand name of ketorolac ophthalmic, approved by the FDA in the following formulation(s):

ACULAR LS (ketorolac tromethamine - solution/drops;ophthalmic)

  • Manufacturer: ALLERGAN
    Approval date: May 30, 2003
    Strength(s): 0.4% [RLD] [AT]

Has a generic version of Acular LS been approved?

A generic version of Acular LS has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Acular LS and have been approved by the FDA:

ketorolac tromethamine solution/drops;ophthalmic

  • Manufacturer: AKORN
    Approval date: November 5, 2009
    Strength(s): 0.4% [AT]
  • Manufacturer: ALCON PHARMS LTD
    Approval date: November 5, 2009
    Strength(s): 0.4% [AT]
  • Manufacturer: APOTEX INC
    Approval date: November 5, 2009
    Strength(s): 0.4% [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Acular LS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Ketorolac tromethamine compositions for treating or preventing ocular pain
    Patent 8,008,338
    Issued: August 30, 2011
    Inventor(s): Muller; Christopher A. & Cheetham; Janet K. & Kuan; Teresa H. & Power; David F.
    Assignee(s): Allergan, Inc.
    Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
    Patent expiration dates:
    • May 24, 2027
      ✓ 
      Patent use: A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 24, 2027
      ✓ 
      Pediatric exclusivity
  • Ketorolac tromethamine compositions for treating or preventing ocular pain
    Patent 8,207,215
    Issued: June 26, 2012
    Inventor(s): Muller; Christopher A. & Cheetham; Janet K. & Kuan; Teresa H. & Power; David F.
    Assignee(s): Allergan, Inc.
    Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
    Patent expiration dates:
    • May 28, 2024
      ✓ 
      Patent use: A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
    • November 28, 2024
      ✓ 
      Pediatric exclusivity
  • Ketorolac tromethamine compositions for treating or preventing ocular pain
    Patent 8,377,982
    Issued: February 19, 2013
    Assignee(s): Allergan Sales, LLC
    Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
    Patent expiration dates:
    • May 28, 2024
      ✓ 
      Patent use: A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
    • November 28, 2024
      ✓ 
      Pediatric exclusivity
  • Ketorolac tromethamine compositions for treating or preventing ocular pain
    Patent 8,541,463
    Issued: September 24, 2013
    Assignee(s): Allergan Sales, LLC
    Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
    Patent expiration dates:
    • May 28, 2024
      ✓ 
      Patent use: A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
    • November 28, 2024
      ✓ 
      Pediatric exclusivity
  • Ketorolac tromethamine compositions for treating or preventing ocular pain
    Patent 8,648,107
    Issued: February 11, 2014
    Assignee(s): Allergan Sales, LLC
    Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
    Patent expiration dates:
    • May 28, 2024
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ATTopical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data.
Hide
(web2)